Teva Branded Pharmaceutical Products R&D
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Teva Branded Pharmaceutical Products R&D sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).
Teva Branded Pharmaceutical Products R&D: 167 sponsored US clinical trials, 6 recruiting.
Teva Branded Pharmaceutical Products R&D sponsors 167 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 131 completed. 89 of these trials are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 13 trials.
Top-decile sponsor footprint
Teva Branded Pharmaceutical Products R&D ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
131 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
167 total, page 1 of 4
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
NCT06807463
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06480552
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
NCT06625177
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013
A Study to Assess New Formulations of TEV-56286
NCT06911567
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
NCT06290102
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
NCT06319170
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
NCT05693935
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
NCT05590377
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05499130
A Study to Test if TEV-53275 is Effective in Relieving Asthma
NCT04847674
A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
NCT04677959
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
NCT04682353
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
NCT03890666
A Study to Test if TEV-48574 is Effective in Relieving Asthma
NCT04545385
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
NCT04464707
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
NCT04458857
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
NCT04200352
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
NCT04157517
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
NCT04041284
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
NCT03813238
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
NCT03965091
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
NCT03893825
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT03571256
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03567291
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
NCT03503318
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
NCT03452943
A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
NCT03347188
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
NCT03308968
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT03215030
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT03256695
Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants
NCT03029000
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
NCT02937168
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
NCT03107052
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
NCT03052725
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma
NCT02969408
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
NCT02945046
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
NCT02964338
Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
NCT02980133
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
NCT02817464
A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma
NCT02680561
To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125
NCT02673567
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
NCT02629861
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 37 |
| Phase 3 | 79 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Teva Branded Pharmaceutical Products R&D pipeline
6 recruiting of 167 indexed (4% open); 131 completed (78%).
Phase mix: 89 late (III/IV) vs 74 early (I/II) (balanced across stages).
Top condition: Asthma (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Teva Branded Pharmaceutical Products R&D: open-pipeline peers nationwide
Peers matched on 167 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Teva Branded Pharmaceutical Products R&D sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 167 trials (± recruiting share)
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Bayer · 4% recruiting · 591 trials
Related
What to do with this Teva Branded Pharmaceutical Products R&D page
167 registered trials is a research-attention snapshot, not an endorsement of Teva Branded Pharmaceutical Products R&D or any single study.
- 6 of Teva Branded Pharmaceutical Products R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Asthma is the condition Teva Branded Pharmaceutical Products R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Teva Branded Pharmaceutical Products R&D pipeline card: 167 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.